Normal Levels Of Vitamin D Is Associated With Improved Treatment Of Some Leukemia Patients – Part 3 of 3
Similar findings were seen in a different group of CLL patients who were followed for 10 years, according to the researchers. “This tells us that vitamin D insufficiency may be the initial potentially modifiable risk factor associated with prognosis in newly diagnosed CLL”. The researchers are planning another study to see if reversing low vitamin D levels in patients will increase their prognosis. The study appears online in the journal Blood ba ki fat kam krna.
Parts: 1 2 3
Normal Levels Of Vitamin D Is Associated With Improved Treatment Of Some Leukemia Patients – Part 2 of 3
And “This watch-and-wait propose to is difficult for patients because they feel there is nothing they can do to help themselves,” Shanafelt said in a Mayo news release. “It appears vitamin D levels may be a modifiable jeopardize factor for leukemia progression. It is simple for patients to have their vitamin D levels checked by their physicians with a blood test. And if they are deficient, vitamin D supplements are extensively available and have minimal side effects”.
This study of 390 CLL patients found that 30 percent of them had insufficient vitamin D levels (less than 25 nanograms per milliliter) at the era of cancer diagnosis. After a median follow-up of three years, patients with insufficient vitamin D levels were 66 percent more likely to have disease progression and to require chemotherapy. They also had a twofold increased chance of death, compared to those with adequate vitamin D levels.
Parts: 1 2 3
Normal Levels Of Vitamin D Is Associated With Improved Treatment Of Some Leukemia Patients – Part 1 of 3
Normal Levels Of Vitamin D Is Associated With Improved Treatment Of Some Leukemia Patients. Patients with a unspecified type of leukemia who had too little vitamin D levels when their cancer was diagnosed saw their disease progress much faster and were two times more likely to die than those with adequate vitamin D levels, a new study finds. Researchers also discovered that increasing vitamin D levels in patients was linked to longer survival times, even after controlling for other factors associated with leukemia progression. This is an notable finding for both patients and doctors, according to the researchers at the Mayo Clinic in Rochester, Minn and the University of Iowa.
The c murrain – chronic lymphocytic leukemia (CLL) – is cancer of the white blood cells (lymphocytes) and mainly affects adults. Although CLL is often diagnosed at an primeval stage, the standard approach is to wait until patients develop symptoms before beginning chemotherapy, explained study author and hematologist Dr Tait Shanafelt.
Parts: 1 2 3
The Use Of Nicotinic Acid In The Treatment Of Heart Disease – Part 3 of 3
Did the fault lie with the laropiprant and not niacin? Armitage is doubtful. She pointed to a prior trial, called AIM-HIGH, which was discontinued pioneer in 2011 when researchers found no benefit to niacin treatment. At the time, some experts said that the smaller population in AIM-HIGH masked any sign of benefit, but Armitage said the unheard of trial’s much bigger study group confirms that niacin probably does not help.
Speaking in February 2013 at the time of the journal’s release of niacin’s safety profile, one US expert was less than impressed by niacin’s performance. The sample “confirms that, for the present moment, there may be little additional benefit with the use of niacin when patients are well treated with the lipid-lowering statin drugs,” said Dr Kevin Marzo, outstanding of cardiology at Winthrop-University Hospital in Mineola, NY. He said that the results of the new trial, along with those from a prior large study, “now may put the final nail in the coffin on niacin-based strategies to vivify HDL and lower cardiovascular events”.
Other tried-and-true approaches may work best. “In addition to statins, our focus should be on continued lifestyle changes such as a Mediterranean diet, complemented with circadian exercise”. The US Food and Drug Administration had been waiting on the new trial results to decide whether to approve niacin/laropiprant for use against heart disease urine ki small ki kya wh hoti hai. But in December 2012, responding to premonitory findings, drug maker Merck said it no longer planned to press for approval from the FDA and in January 2013 delayed niacin/laropiprant from markets worldwide.
Parts: 1 2 3
The Use Of Nicotinic Acid In The Treatment Of Heart Disease – Part 2 of 3
They received either 2 grams of extended-release niacin with 40 milligrams of laropiprant or matching placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an usual of almost four years.
Besides showing no helpful effect on heart health outcomes, the team noted that people taking niacin had about the same amount of heart-related events (13,2 percent) as those who took a placebo a substitute (13,7 percent). Side effects were common. As already reported online Feb 26, 2013 in the European Heart Journal, by the end of the study, 25 percent of patients taking niacin asset laropiprant had stopped their treatment, compared with 17 percent of the patients taking a placebo.
And “The main reason for patients stopping the therapy was because of adverse side effects, such as itching, rashes, flushing, indigestion, diarrhea, diabetes and muscle problems,” Armitage said at the time in a journal news release. “We found that patients allocated to the exploratory treatment were four times more likely to stop for skin-related reasons, and twice as likely to stop because of gastrointestinal problems or diabetes-related problems”. Patients taking niacin and laropiprant had a more than fourfold increased jeopardize of muscle pain or weakness compared to the placebo group, the team noted.
Parts: 1 2 3
The Use Of Nicotinic Acid In The Treatment Of Heart Disease – Part 1 of 3
The Use Of Nicotinic Acid In The Treatment Of Heart Disease. Combining the vitamin niacin with a cholesterol-lowering statin cure appears to provide patients no benefit and may also increase side effects, a new study indicates. It’s a disappointing result from the largest-ever study of niacin for heart patients, which involved almost 26000 people. In the study, patients who added the B-vitamin to the statin medication Zocor saw no added benefit in terms of reductions in heart-related death, non-fatal heart attack, stroke, or the need for angioplasty or circumvent surgeries.
The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were taking an inactive placebo, according to a team reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. “We are saddened that these results did not show benefits for our patients,” study lead author Jane Armitage, a professor at the University of Oxford in England, said in a meeting news release. “Niacin has been second-hand for many years in the belief that it would help patients and prevent heart attacks and stroke, but we now know that its adverse side effects outweigh the benefits when used with current treatments”.
Niacin has long been cast-off to boost levels of “good” HDL cholesterol and decrease levels of “bad” LDL cholesterol and triglycerides (fats) in the blood in people at risk for heart disease and stroke. However, niacin also causes a mass of side effects, including flushing of the skin. A drug called laropiprant can reduce the incidence of flushing in people taking niacin. This new study included patients with narrowing of the arteries.
Parts: 1 2 3
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks – Part 3 of 3
He is not affiliated with the new study. “Eliminating a altogether week per month of headaches is a huge gain for chronic migraine sufferers and translates into big improvements in treatment satisfaction and quality of life. This treatment will make a huge disagreement for millions of migraine sufferers with chronic migraine”.
The results do mirror what Lipton has seen in his practice. “This shows that the treatment can give chronic migraine sufferers their lives back”.
Dr Robert Duarte, top banana of the Pain Center at North Shore-Long Island Jewish Health System in Manhasset, NY, said that the new device should not be considered a first-line treatment for migraine, however. “You paucity to be evaluated by a headache specialist, and make sure all treatment options are tried before installing a stimulator, but it is an option and there is definitely evidence that it works”.
Duarte is not affiliated with the new study. “It is not a cure, but a healing option that can reduce frequency and intensity of headaches in some people” pro extender video en gabes. Doctors can also do a trial run using an external stimulator to see if it will work before implanting the device.
Parts: 1 2 3
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks – Part 2 of 3
The pain reduction seen in the study did fall short of FDA standards, which call for a 50 percent reduction in pain. “The device is invisible to the eye, but not to the touch”. The implantation course involves local anesthesia along with conscious sedation so you are awake, but not fully aware.
There may be some mild pain associated with this surgery. Study co-author Dr Joel Saper, stumble and director of Michigan Head Pain and Neurological Institute in Ann Arbor, and a member of the advisory board for the Migraine Research Foundation, said this therapy could be an important option for some multitude with migraines.
And “There were numerous patients who did benefit in terms of pain control and quality of life. We don’t have any universally effective therapies for migraine, so we don’t ever expect everyone to have complete results, but for those few that it works in, it’s life-changing”.
But “it is surgical and there are risks to surgery, and there are unknowns such as how long the effects will last”. Risks of the new neurostimulation procedure may include infection and the emblem can sometimes dislodge.
Saper has not received any compensation from the device manufacturer. “Occipital nerve stimulation is a treatment of great promise for patients with intractable chronic migraine,” said Dr Richard B Lipton, guide of the Headache Center at Albert Einstein College of Medicine/Montefiore Medical Center in the Bronx and a board member of the Migraine Research Foundation.
Parts: 1 2 3
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks – Part 1 of 3
Implantable Devices Are Not A Panacea, But The Ability To Relieve Migraine Attacks. An implantable utensil hidden in the nape of the neck may cruel more headache-free days for people with severe migraines that don’t respond to other treatments, a new study suggests. More than 36 million Americans get migraine headaches, which are marked by keen pain, sensitivity to light and sound, nausea and vomiting, according to the Migraine Research Foundation. Medication and lifestyle changes are the first-line treatments for migraine, but not everyone improves with these measures.
The St Jude Medical Genesis neurostimulator is a short, withered strip that is implanted behind the neck. A battery pack is then implanted elsewhere in the body. Activating the device stimulates the occipital nerve and can gloomy the pain of migraine headache. “There are a large number of patients for whom nothing works and whose lives are ruined by the daily pain of their migraine headache, and this device has the potential to help some of them,” said investigate author Dr Stephen D Silberstein, director of the Jefferson Headache Center in Philadelphia.
The study, which was funded by device manufacturer St Jude Medical Inc, is slated for launch on Thursday at the International Headache Congress in Berlin, and is the largest study to date on the device. The company is now seeking approval for the device in Europe and then plans to submit their data to the US Food and Drug Administration for consent in the United States.
Researchers tested the new device in 157 people who had severe migraines about 26 days out of each month. After 12 weeks, those who received the recent device had seven more headache-free days per month, compared to one more headache-free day per month seen among people in the control group.
Individuals in the control arm did not receive stimulation until after the key 12 weeks. Study participants who received the stimulator also reported less severe headaches and improvements in their quality of life. After one year, 66 percent of people in the study said they had sterling or good pain relief.
Parts: 1 2 3